The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 23 November 2004, www.theannals.com, DOI 10.1345/aph.1E248.
 The Annals of Pharmacotherapy: Vol. 39, No. 1, pp. 141-145. DOI 10.1345/aph.1E248
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caballero, J.
Right arrow Articles by Nahata, M. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caballero, J.
Right arrow Articles by Nahata, M. C

DRUG INFORMATION ROUNDS

Use of Selective Serotonin-Reuptake Inhibitors in the Treatment of Depression in Adults with HIV

Joshua Caballero, PharmD

at time of writing, Pharmacotherapy Fellow, College of Pharmacy, Ohio State University, Columbus, OH; now, Assistant Professor, Cooperative Pharmacy Program, University of Texas–Pan American, Edinburg, TX

Milap C Nahata, PharmD

Professor of Pharmacy and Division Chair, College of Pharmacy; Professor of Pediatrics and Internal Medicine, College of Medicine and Public Health, Ohio State University and Children's Hospital, Columbus, OH

Reprints: Dr. Nahata, College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210-1291, fax 614/292-1335

OBJECTIVE: To review the safety and efficacy of selective serotonin-reuptake inhibitors (SSRIs) for the treatment of depression in adults with HIV.

DATA SOURCES: We searched Pre-MEDLINE and MEDLINE (1966–May 2004) using terms including generic names of antidepressants and antiretrovirals, depression, HIV, and acquired immunodeficiency syndrome. All English-language articles were included in this review.

DATA SYNTHESIS: SSRIs may be effective and better tolerated than tricyclic antidepressants in HIV-positive adults. SSRIs did not appear to affect CD4+ cell counts.

CONCLUSIONS: Controlled trials comparing SSRIs are lacking; thus, it is difficult to determine whether one SSRI is more efficacious than another. It appears that most SSRIs may be used in HIV-positive adults. If drug–drug interactions are a concern, sertraline, citalopram, and possibly escitalopram may be considered.

Key Words: adults, antiretrovirals, selective serotonin-reuptake inhibitors

Published Online, November 23, 2004. www.theannals.com, DOI 10.1345/aph.1E248




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.